IPRIPR2023-01044Terminated-Settled
Novartis Gene Therapies, Inc. et al.v.Genzyme Corporation et al.
IPR challenge of US 10429288.
Type
IPR
Filed
Jun 30, 2023
Instituted
Jan 9, 2024
Decided
Mar 4, 2024
Patent
Application
15544498
Inventor
Catherine R. O'RIORDAN et al
Granted
Oct 1, 2019
01
Timeline
3 milestones
2023-06-30Petition filed
2024-01-09Institution
2024-03-04Terminated
02
Parties & counsel
Petitioner
Novartis Gene Therapies, Inc. et al.
Counsel
Livingstone, Johnet al
Patent Owner
Genzyme Corporation et al.
Counsel
Antons, Amandaet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →